{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:22:59Z","timestamp":1761513779774,"version":"3.37.3"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,3,7]],"date-time":"2016-03-07T00:00:00Z","timestamp":1457308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,3,7]],"date-time":"2016-03-07T00:00:00Z","timestamp":1457308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s40261-016-0385-z","type":"journal-article","created":{"date-parts":[[2016,3,7]],"date-time":"2016-03-07T11:13:08Z","timestamp":1457349188000},"page":"401-411","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Safety Profile of Artemether-Lumefantrine: A Cohort Event Monitoring Study in Public Health Facilities in Tanzania"],"prefix":"10.1007","volume":"36","author":[{"given":"Alambo K.","family":"Mssusa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam M.","family":"Fimbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex F.","family":"Nkayamba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry F.","family":"Irunde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiiti B.","family":"Sillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danstan H.","family":"Shewiyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geraldine","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omary M.","family":"Minzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,3,7]]},"reference":[{"key":"385_CR1","volume-title":"Guidelines for the treatment of malaria","author":"World Health Organization","year":"2010","unstructured":"World Health Organization. Guidelines for the treatment of malaria. 2nd ed. Geneva: World Health Organization; 2010.","edition":"2"},{"key":"385_CR2","unstructured":"World Health Organization\/UNICEF. The Africa Malaria Report. Geneva: World Health Organization\/UNICEF 2003. Report No.: WHO\/CDS\/MAL\/2003.1093."},{"key":"385_CR3","unstructured":"United Republic of Tanzania Ministry of Health and Social Welfare. National Guidelines for Diagnosis and Treatment of Malaria. Malaria control series 11, National Malaria Control Programme. Dar es Salaam; 2006."},{"issue":"6","key":"385_CR4","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.trstmh.2004.09.013","volume":"99","author":"C Falade","year":"2005","unstructured":"Falade C, Makanga M, Premji Z, Ortmann C-E, Stockmeyer M, de Palacios PI. Efficacy and safety of artemether\u2013lumefantrine (Coartem\u00ae) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg. 2005;99(6):459\u201367. doi:10.1016\/j.trstmh.2004.09.013.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"1","key":"385_CR5","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1371\/journal.pctr.0010007","volume":"1","author":"H Bukirwa","year":"2006","unstructured":"Bukirwa H, Yeka A, Kamya MR, Talisuna A, Banek K, Bakyaita N, et al. Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda. PLoS Clin Trials. 2006;1(1):e7. doi:10.1371\/journal.pctr.0010007.","journal-title":"PLoS Clin Trials."},{"issue":"5\u20136","key":"385_CR6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4269\/ajtmh.2001.64.247","volume":"64","author":"G Lefevre","year":"2001","unstructured":"Lefevre G, Looareesuwan S, Treeprasertsuk S, Krudsood S, Silachamroon U, Gathmann I, et al. A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg. 2001;64(5\u20136):247\u201356.","journal-title":"Am J Trop Med Hyg"},{"issue":"4","key":"385_CR7","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.trstmh.2006.06.010","volume":"101","author":"CI Fanello","year":"2007","unstructured":"Fanello CI, Karema C, van Doren W, Van Overmeir C, Ngamije D, D\u2019Alessandro U. A randomised trial to assess the safety and efficacy of artemether-lumefantrine (Coartem) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwanda. Trans R Soc Trop Med Hyg. 2007;101(4):344\u201350. doi:10.1016\/j.trstmh.2006.06.010.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"9652","key":"385_CR8","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(08)61492-0","volume":"372","author":"S Abdulla","year":"2008","unstructured":"Abdulla S, Sagara I, Borrmann S, D\u2019Alessandro U, Gonzalez R, Hamel M, et al. Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial. Lancet. 2008;372(9652):1819\u201327. doi:10.1016\/s0140-6736(08)61492-0.","journal-title":"Lancet"},{"key":"385_CR9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.5005\/jp\/books\/11442_7","volume-title":"Postmarketing surveillance. Textbook of pharmacovigilance","author":"M Sharma","year":"2011","unstructured":"Sharma M, Gupta SK. Postmarketing surveillance. Textbook of pharmacovigilance. New Delhi: Jaypee Brothers; 2011. p. 75\u201392."},{"issue":"8","key":"385_CR10","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00228-008-0475-9","volume":"64","author":"L Harmark","year":"2008","unstructured":"Harmark L, van Grootheest AC. Pharmacovigilance: methods, recent developments and future perspectives. Eur J Clin Pharmacol. 2008;64(8):743\u201352. doi:10.1007\/s00228-008-0475-9.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"385_CR11","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf Int J Med Toxicol Drug Exp. 2006;29(5):385\u201396.","journal-title":"Drug Saf Int J Med Toxicol Drug Exp"},{"key":"385_CR12","volume-title":"The importance of pharmacovigilance: safety monitoring of medicinal products","author":"World Health Organization","year":"2002","unstructured":"World Health Organization. The importance of pharmacovigilance: safety monitoring of medicinal products. Geneva: World Health Organization; 2002."},{"key":"385_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1475-2875-10-57","volume":"10","author":"A Kuemmerle","year":"2011","unstructured":"Kuemmerle A, Dodoo AN, Olsson S, Van Erps J, Burri C, Lalvani PS. Assessment of global reporting of adverse drug reactions for anti-malarials, including artemisinin-based combination therapy, to the WHO Programme for International Drug Monitoring. Malar J. 2011;10:57. doi:10.1186\/1475-2875-10-57.","journal-title":"Malar J"},{"key":"385_CR14","unstructured":"World Health Organization. World Malaria Report Geneva: World Health Organization 2011."},{"key":"385_CR15","volume-title":"Tanzania: quantification and supply planning for anti-malarial medicines","author":"E Takang","year":"2008","unstructured":"Takang E, Duberstein S, Rosche T, Nyonyi J, Shango W. Tanzania: quantification and supply planning for anti-malarial medicines. Va: Arlington; 2008."},{"key":"385_CR16","volume-title":"A practical handbook on the pharmacovigilance of antimalarial medicines","author":"World Health Organization","year":"2008","unstructured":"World Health Organization. A practical handbook on the pharmacovigilance of antimalarial medicines. Geneva: WHO; 2008."},{"key":"385_CR17","volume-title":"A practical handbook on the pharmacovigilance of antiretroviral medicines","author":"World Health Organization","year":"2009","unstructured":"World Health Organization. A practical handbook on the pharmacovigilance of antiretroviral medicines. Geneva: WHO; 2009."},{"key":"385_CR18","volume-title":"A practical handbook on the pharmacovigilance of medicines used in the treatment of Tuberculosis: enhancing the safety of the TB patient","author":"World Health Organization","year":"2012","unstructured":"World Health Organization. A practical handbook on the pharmacovigilance of medicines used in the treatment of Tuberculosis: enhancing the safety of the TB patient. Geneva: WHO; 2012."},{"key":"385_CR19","unstructured":"Uppsala Monitoring Centre. Glossary of terms used in Pharmacovigilance 2015. http:\/\/www.who-umc.org\/graphics\/28401.pdf. Accessed 22 July 2015."},{"key":"385_CR20","unstructured":"MSSO (Maintenance and Support Services Organization). MedDRA: medical dictionary for regulatory activities. http:\/\/www.meddra.org\/. Accessed 24 June 2015."},{"key":"385_CR21","unstructured":"Uppsala Monitoring Centre. WHO Drug Dictionary Enhanced. 2015. http:\/\/www.who-umc.org\/DynPage.aspx?id=98105&mn1=7347&mn2=7252&mn3=7254&mn4=7338. Accessed 22 July 2015."},{"issue":"5","key":"385_CR22","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/009286150804200501","volume":"42","author":"M Lindquist","year":"2008","unstructured":"Lindquist M. VigiBase, the WHO Global ICSR Database System: basic facts. Drug Inf J. 2008;42(5):409\u201319. doi:10.1177\/009286150804200501.","journal-title":"Drug Inf J"},{"key":"385_CR23","unstructured":"Uppsala Monitoring Centre. The use of the WHO-UMC system for standardised case causality assessment. Uppsala Monitoring Centre. 2012. http:\/\/www.who-umc.org\/Graphics\/26649.pdf. Accessed 3 Mar 2015."},{"key":"385_CR24","unstructured":"IBM. SPSS software: Predictive analytics software and solutions IBM. 2015. http:\/\/www-01.ibm.com\/software\/analytics\/spss\/. Accessed Feb 2014."},{"key":"385_CR25","unstructured":"Novartis Pharmaceuticals Corporation. Full Prescribing Information: Coartem (artemether\/lumefantrine)\u2014Novartis Pharmaceuticals Corporation. In: Physicians Desk Reference (PDR). 2015. http:\/\/www.pdr.net\/full-prescribing-information\/coartem?druglabelid=419. Accessed Feb 2014."},{"issue":"9","key":"385_CR26","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s40264-013-0044-8","volume":"36","author":"PU Bassi","year":"2013","unstructured":"Bassi PU, Osakwe AI, Isah A, Suku C, Kalat M, Jalo I, et al. Safety of Artemisinin-based combination therapies in Nigeria: a cohort event monitoring study. Drug Saf. 2013;36(9):747\u201356. doi:10.1007\/s40264-013-0044-8.","journal-title":"Drug Saf"},{"issue":"Suppl 1","key":"385_CR27","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1186\/1475-2875-8-S1-S6","volume":"8","author":"C Falade","year":"2009","unstructured":"Falade C, Manyando C. Safety profile of Coartem: the evidence base. Malar J. 2009;8(Suppl 1):S6. doi:10.1186\/1475-2875-8-s1-s6.","journal-title":"Malar J"},{"issue":"2","key":"385_CR28","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1046\/j.1365-2125.2003.01875.x","volume":"57","author":"PA Routledge","year":"2004","unstructured":"Routledge PA, O\u2019Mahony MS, Woodhouse KW. Adverse drug reactions in elderly patients. Br J Clin Pharmacol. 2004;57(2):121\u20136.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"385_CR29","doi-asserted-by":"publisher","first-page":"601","DOI":"10.2174\/138920011796504527","volume":"12","author":"S Shi","year":"2011","unstructured":"Shi S, Klotz U. Age-related changes in pharmacokinetics. Curr Drug Metab. 2011;12(7):601\u201310.","journal-title":"Curr Drug Metab"},{"key":"385_CR30","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1186\/1475-2875-12-385","volume":"12","author":"O Egunsola","year":"2013","unstructured":"Egunsola O, Oshikoya KA. Comparative safety of artemether-lumefantrine and other artemisinin-based combinations in children: a systematic review. Malar J. 2013;12:385. doi:10.1186\/1475-2875-12-385.","journal-title":"Malar J"},{"issue":"6","key":"385_CR31","doi-asserted-by":"crossref","first-page":"991","DOI":"10.4269\/ajtmh.2006.74.991","volume":"74","author":"M Makanga","year":"2006","unstructured":"Makanga M, Premji Z, Falade C, Karbwang J, Mueller EA, Andriano K, et al. Efficacy and safety of the six-dose regimen of artemether-lumefantrine in pediatrics with uncomplicated Plasmodium falciparum malaria: a pooled analysis of individual patient data. Am J Trop Med Hyg. 2006;74(6):991\u20138.","journal-title":"Am J Trop Med Hyg"},{"issue":"1\u20132","key":"385_CR32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.actatropica.2006.09.007","volume":"100","author":"EA Mueller","year":"2006","unstructured":"Mueller EA, van Vugt M, Kirch W, Andriano K, Hunt P, de Palacios PI. Efficacy and safety of the six-dose regimen of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in adolescents and adults: a pooled analysis of individual patient data from randomized clinical trials. Acta Trop. 2006;100(1\u20132):41\u201353. doi:10.1016\/j.actatropica.2006.09.007.","journal-title":"Acta Trop"},{"issue":"Suppl 1","key":"385_CR33","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/0035-9203(94)90469-3","volume":"88","author":"TG Brewer","year":"1994","unstructured":"Brewer TG, Peggins JO, Grate SJ, Petras JM, Levine BS, Weina PJ, et al. Neurotoxicity in animals due to arteether and artemether. Trans R Soc Trop Med Hyg. 1994;88(Suppl 1):S33\u20136.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"18","key":"385_CR34","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/NEJM199705013361818","volume":"336","author":"LG Miller","year":"1997","unstructured":"Miller LG, Panosian CB. Ataxia and slurred speech after artesunate treatment for falciparum malaria. N Engl J Med. 1997;336(18):1328. doi:10.1056\/nejm199705013361818.","journal-title":"N Engl J Med"},{"issue":"6","key":"385_CR35","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1086\/517789","volume":"28","author":"Z Elias","year":"1999","unstructured":"Elias Z, Bonnet E, Marchou B, Massip P. Neurotoxicity of artemisinin: possible counseling and treatment of side effects. Clin Infect Dis Off Publ Infect Dis Soc Am. 1999;28(6):1330\u20131. doi:10.1086\/517789.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"5","key":"385_CR36","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.trstmh.2003.11.001","volume":"98","author":"S Toovey","year":"2004","unstructured":"Toovey S, Jamieson A. Audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether. Trans R Soc Trop Med Hyg. 2004;98(5):261\u20137. doi:10.1016\/j.trstmh.2003.11.001.","journal-title":"Trans R Soc Trop Med Hyg."},{"issue":"8","key":"385_CR37","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1473-3099(07)70187-1","volume":"7","author":"NJ White","year":"2007","unstructured":"White NJ. Cardiotoxicity of antimalarial drugs. Lancet Infect Dis. 2007;7(8):549\u201358. doi:10.1016\/s1473-3099(07)70187-1.","journal-title":"Lancet Infect Dis"},{"key":"385_CR38","unstructured":"Cousin M, Kummerer S, Lef\u00e8vre G, Marrast AC, Stein D, Weaver M. Coartem\u00ae(artemether-lumefantrine) Tablets for the treatment of malaria in patients with acute, uncomplicated infections due to Plasmodium falciparum or mixed infections including P. falciparum. NDA 22-268. Advisory Committee Briefing Book: Novartis. 2008 October 28."},{"issue":"2","key":"385_CR39","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/(SICI)1099-1557(199803\/04)7:2<79::AID-PDS330>3.0.CO;2-1","volume":"7","author":"DM Coulter","year":"1998","unstructured":"Coulter DM. The New Zealand intensive medicines monitoring programme. Pharmacoepidemiol Drug Saf. 1998;7(2):79\u201390. doi:10.1002\/(SICI)1099-1557(199803\/04)7:2<79:AID-PDS330>3.0.CO;2-1.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"385_CR40","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1046\/j.1365-2125.1998.00774.x","volume":"46","author":"RD Mann","year":"1998","unstructured":"Mann RD. Prescription-event monitoring\u2014recent progress and future horizons. Br J Clin Pharmacol. 1998;46(3):195\u2013201.","journal-title":"Br J Clin Pharmacol"},{"key":"385_CR41","doi-asserted-by":"publisher","unstructured":"Layton D, Shakir SA. Prescription Event Monitoring (PEM)\u2014the evolution to the new modified PEM and its support of risk management. In: Andrews EB, Moore N, editors. Mann\u2019s pharmacovigilance. 3rd ed. Oxford: Wiley; 2014. doi: 10.1002\/9781118820186.ch22","DOI":"10.1002\/9781118820186.ch22"},{"key":"385_CR42","volume-title":"Ministry of health and social welfare","author":"The Parliament of Tanzania","year":"2003","unstructured":"The Parliament of Tanzania. Ministry of health and social welfare. Tanzania: The Tanzania Food, Drugs and Cosmetics Act; 2003."},{"key":"385_CR43","unstructured":"Council for International Organizations of Medical Sciences (CIOMS). International ethical guidelines for epidemiological studies. Geneva: CIOMS; 2009."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-016-0385-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-016-0385-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-016-0385-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-016-0385-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T14:17:42Z","timestamp":1659104262000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-016-0385-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,7]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["385"],"URL":"https:\/\/doi.org\/10.1007\/s40261-016-0385-z","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"type":"print","value":"1173-2563"},{"type":"electronic","value":"1179-1918"}],"subject":[],"published":{"date-parts":[[2016,3,7]]},"assertion":[{"value":"7 March 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Cohort Event Monitoring of medicines is part of drug safety monitoring and is under the jurisdiction of Tanzania Food and Drugs Authority (TFDA) as per the Tanzania Food, Drugs and Cosmetics Act, Cap 219 section\u00a05 (C) []. The study was endorsed by TFDA Pharmacovigilance Technical Committee. This study was observational and did not interfere with the routine practice in health facilities. However, all patients were informed of the purpose of undertaking the monitoring and were requested to provide verbal consent as per requirements []. Ethical principles for conducting medical research were considered during implementation of the programme.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Considerations"}},{"value":"Ms. Alambo K. Mssusa, Mr. Adam M. Fimbo, Dr. Alex F. Nkayamba, Mr. Henry F. Irunde, Mr. Hiiti B. Sillo, Dr. Danstan H. Shewiyo, Dr. Geraldine Hill and Prof. Omary M. Minzi declare they have no direct conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}